The Indonesian Ministry of Health has approved SS Innovations’s SSi Mantra Surgical Robotic System for clinical use.

The system is designed to be cost-effective and versatile across a wide range of surgical procedures. It supports advanced, affordable, and accessible robotic surgery.

Said to be the first surgical robotic technology manufactured in India, the SSi Mantra system has demonstrated its efficacy with more than 100 robotic cardiac surgeries completed in just over a year.

In India, the system is clinically validated for use in over 70 different surgical types.

SS Innovation chairman and CEO Dr Sudhir Srivastava said: “With the entry of the SSi Mantra to the Indonesian market, we believe that we can be instrumental in increasing access to and decreasing costs of robotic surgery options.

“We look forward to broadening surgical horizons for Indonesians and continuing to expand our innovative surgical services and options across the globe.”

Neuro Medika Sejahtera is serving as the distributor of SSi Mantra in Indonesia.

Neuro Medika Sejahtera CEO Mohammad Ridwan said: “I was very satisfied to see the quality of the SSi Mantra and the advancement offered by the SSi Maya, the company’s mixed-reality software application. I believe that SS Innovations offers a practical and cost-effective solution to help expand robotic surgery access in Indonesia.”

The robotic system is equipped to provide the capabilities for multi-speciality usage, including head and neck, gynaecology, cardiothoracic, urology, general surgery and more.

It features 3D 4K vision open-console design, a modular arm configuration, and superior ergonomics.

SS Innovations is also pursuing regulatory approvals in other major markets, including the US and the European Union.

The company expects to receive the US Food and Drug Administration approval and CE Mark certification by next year.